clinical trial · NCT05157269
Trial to Evaluate Nitazoxanide for Treatment of Mild COVID-19 in Subjects Not at High Risk of Severe Illness
Romark Laboratories L.C.·phase3·withdrawn
COVID-19NitazoxanidePlaceboVitamin Super-B Complex
brief summary
The purpose of this study is to determine whether nitazoxanide (NTZ) is safe and effective for treatment of mild COVID-19 illness. Adults and adolescent participants will be followed for approximately 28 days.
started
Aug 1, 2024
primary completion
Mar 1, 2025
completion
Mar 1, 2025
last updated
Sep 24, 2024
official title
Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild COVID-19 in Subjects Not at High Risk of Severe Illness
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol